Illumina unveils preliminary fourth-quarter revenue that tops estimates

Investing.com -- Illumina (NASDAQ:ILMN) has said it will report consolidated revenue in the fourth quarter that will top analysts' estimates, sending shares in the gene-sequencing products maker higher in early U.S. trade on Tuesday.

In an update unveiling its preliminary financial results, San Diego-based Illumina said consolidated sales during the quarter would rise by 3% compared to the same period last year to $1.12 billion. Bloomberg consensus expectations had placed the figure at $1.07B.

Illumina, which makes DNA sequencers used to accelerate drug development, added that it shipped 79 of its NovaSeq X instruments in the fourth quarter and 352 of the devices over the course of its 2023 fiscal year. The company has claimed that the next-generation system can produce 2.5 times more whole genomes per year than earlier sequencers.

Illumina plans to release its final fourth-quarter and full-year earnings after the close of trading on Feb. 8.

The preliminary numbers come after the group said last month that it will offload cancer screening start-up Grail by the second quarter of 2024.

Grail was acquired by Illumina in 2021 in an agreement that valued the seller of a blood test designed for the early detection of cancer at $7.1 billion. However, the agreement faced heavy scrutiny, particularly after it was completed without the formal approval of the European Commission. The divesiture of Grail would be "consistent" with an order from Brussels, Illumina noted.

The U.S. Federal Trade Commission also pushed back against the deal, flagging that Illumina could deny crucial inputs into cancer-detecting blood tests made by Grail's rivals. A federal appeals court found that while the FTC was right to issue the challenge, it must conduct a new review of the purchase. Illumina said it would not appeal the ruling.

Many investors in Illumina, including billionaire Carl Icahn, had voiced their opposition to the Grail deal as well. Earlier this year, Icahn, arguing that the acquisition amounted to a breach of Illumina's fiduciary duties, helmed a proxy battle that led to the resignation of former boss Francis deSouza.

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201)

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

www.onefinancialmarkets.com is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: